[Form 3] Cytek Biosciences, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Form 3 overview: Cytek Biosciences, Inc. (CTKB) filed an Initial Statement of Beneficial Ownership for newly appointed director Richard Chin covering the reportable event date of 06/18/2025. The filing is required under Section 16(a) to disclose any equity interest held by insiders at the moment they become subject to reporting obligations.

Key disclosure: Table I and Table II are blank and the “Explanation of Responses” section states “No securities are beneficially owned.” Accordingly, Dr. Chin reports zero direct or indirect ownership of Cytek common shares or derivative securities as of the event date.

Governance context: Because Form 3 establishes the baseline from which future changes will be measured, investors can expect subsequent Form 4 filings if and when the director acquires stock or options. The document was signed by attorney-in-fact Valerie Barnett on 06/20/2025.

Positive

• None.

Negative

• Director reports no beneficial ownership, indicating the board member currently has no economic stake aligned with shareholders.

Insights

Corporate Governance Expert

TL;DR: New director Richard Chin reports zero CTKB ownership; neutral governance signal pending future equity grants.

The Form 3 creates a legal baseline showing Dr. Chin holds no Cytek shares or options at appointment. While it does not violate governance norms, many investors prefer directors to retain an economic stake that aligns incentives with shareholders. Companies often award equity shortly after onboarding, so forthcoming grants would typically appear in subsequent Form 4 filings. Until then, the lack of ownership neither improves nor harms governance metrics but is worth monitoring.

Securities Analyst

TL;DR: Filing is procedural; absence of holdings has minimal immediate market impact.

This low-complexity Form 3 contains no financial metrics, transaction data, or ownership shifts, therefore it is unlikely to influence CTKB valuation or trading volumes. The director’s zero share position may invite questions on alignment, but in practice, equity compensation packages often follow shortly. Overall market impact is neutral, and investors should watch for Form 4 updates rather than act on this disclosure alone.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chin Richard

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BOULEVARD

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/18/2025

3. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Valerie Barnett , Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Cytek Biosciences (CTKB) file a Form 3 on 06/20/2025?

To disclose new director Richard Chin’s initial beneficial ownership status as required under Section 16(a).

How many Cytek shares does Richard Chin own according to the Form 3?

The filing states no securities are beneficially owned, so share ownership is zero.

Does the Form 3 include any stock options or derivative securities for Dr. Chin?

No. Table II is blank, indicating no derivative securities are held.

When was the Form 3 for CTKB signed and by whom?

It was signed on 06/20/2025 by Valerie Barnett acting as Attorney-in-Fact.

Will future equity grants to Richard Chin be disclosed?

Yes, any subsequent acquisitions must be reported on Form 4 within two business days.